Emilio Fernandez-Egea
Overview
Explore the profile of Emilio Fernandez-Egea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolpe N, Perrottelli A, Giuliani L, Yang Z, Rekhi G, Jones P, et al.
Eur Neuropsychopharmacol
. 2025 Feb;
93:68-76.
PMID: 40020376
The negative symptoms of schizophrenia can determine functional outcome in patients. Despite its clinical significance, no treatment exists to date, as numerous pharmacological and non-pharmacological clinical trials have failed to...
2.
Fernandez-Egea E, McCutcheon R
Br J Psychiatry
. 2024 Oct;
226(1):1-3.
PMID: 39359180
Oloyede and colleagues advocate for updating haematological monitoring requirements for clozapine, arguing that current protocols overestimate the risk of clozapine-induced agranulocytosis. Their research suggests that stringent monitoring may unnecessarily limit...
3.
Fernandez-Egea E, Flanagan R, Taylor D, Gaughran F, Lawrie S, Jenkins C, et al.
Br J Psychiatry
. 2024 Oct;
225(3):357-359.
PMID: 39354861
While clozapine has risks, relative risk of fatality is overestimated. The UK pharmacovigilance programme is efficient, but comparisons with other drugs can mislead because of reporting variations. Clozapine actually lowers...
4.
Dal Santo F, Garcia-Portilla M, Fernandez-Egea E, Gonzalez-Blanco L, Saiz P, Giordano G, et al.
Schizophrenia (Heidelb)
. 2024 Sep;
10(1):81.
PMID: 39349504
The Positive and Negative Syndrome Scale (PANSS) is the most widely used rating scale to assess psychotic symptoms in patients with schizophrenia and other primary psychoses. However, a definitive consensus...
5.
Fernandez-Egea E, Chen S, Sanguesa E, Gasso P, Biria M, Plaistow J, et al.
Br J Psychiatry
. 2024 Apr;
224(5):164-169.
PMID: 38652060
Background: A significant proportion of people with clozapine-treated schizophrenia develop 'checking' compulsions, a phenomenon yet to be understood. Aims: To use habit formation models developed in cognitive neuroscience to investigate...
6.
Kirkpatrick B, Fernandez-Egea E
Span J Psychiatry Ment Health
. 2024 Apr;
PMID: 38591771
No abstract available.
7.
Kirkpatrick B, Fernandez-Egea E
Eur Neuropsychopharmacol
. 2024 Mar;
83:30-31.
PMID: 38547544
No abstract available.
8.
Sanguesa E, Fernandez-Egea E, Concha J, Garcia C, Ribate M
Biomedicines
. 2024 Mar;
12(3).
PMID: 38540209
Managing schizophrenia with clozapine poses a significant challenge due to prevalent therapeutic failures. The increasing interest in personalized medicine underscores the importance of integrating pharmacogenetic information for effective pharmacotherapeutic monitoring...
9.
Garcia-Rizo C, Crespo-Facorro B, Oliveira C, Gomez-Revuelta M, Kirkpatrick B, Son J, et al.
Schizophr Res
. 2024 Mar;
266:216-226.
PMID: 38428119
Background: Patients with schizophrenia exhibit a reduced life expectancy mainly due to medical-related pathologies which might have been initiated due to stressful events during fetal development. Indeed, intra-uterus growth patterns...
10.
Barnham I, Saleh Y, Hussain M, Fernandez-Egea E
Span J Psychiatry Ment Health
. 2024 Feb;
PMID: 38331322
No abstract available.